PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1407982
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1407982
Global Continuous Bioprocessing Market is valued at approximately USD 125.6 million in 2022 and is anticipated to grow with a healthy growth rate of more than 22.50% during the forecast period 2023-2030. Continuous bioprocessing refers to a method of manufacturing in the biopharmaceutical industry where the production steps for biological products occur without interruption, as opposed to traditional batch processing. The Continuous Bioprocessing Market is expanding because of factors such as the increasing number of contract development and manufacturing organizations and the rising demand for biopharmaceuticals. In a continuous bioprocessing setup, various stages of the production process, such as cell culture, harvest, purification, and formulation, are connected in a continuous flow rather than being conducted as separate, distinct batches. As a result, the demand for Continuous Bioprocessing has progressively increased in the international market during the forecast period 2023-2030.
Continuous bioprocessing has the potential to reduce overall manufacturing costs by improving resource utilization, minimizing downtime, and optimizing production processes. CDMOs, as service providers, are often focused on delivering cost-effective solutions to their clients. According to Statista, the Contract Development and Manufacturing Organization (CDMO) market accounted for USD 115.5 billion in 2020 and is projected to reach up to USD 223.5 billion by the year 2030. Another important factor that drives the Continuous Bioprocessing Market is the increasing demand for biopharmaceuticals. Continuous bioprocessing can contribute to improved product quality and consistency. Real-time monitoring and control mechanisms enhance the ability to maintain desired product attributes, reducing variability and ensuring high-quality biopharmaceuticals. In addition, as per Statista, the global pharmaceutical market accounted for USD 1.48 trillion in 2022. This represents a marginal gain from 2021 when the market was valued at USD 1.42 trillion. Moreover, the increasing number of contract development and manufacturing organizations and rising demand for biopharmaceuticals are anticipated to create lucrative growth opportunities for the market over the forecast period. However, high capital investments and stringent regulatory requirements are going to impede overall market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Continuous Bioprocessing Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the biopharmaceutical companies forming strategic partnerships and collaborations to expand their market presence in the region. The region's dominant performance is anticipated to propel the overall demand for Continuous Bioprocessing. Furthermore, Asia Pacific is expected to grow fastest over the forecast period, owing to factors such as bioprocessing technology and partnership expansions, as well as collaborations with key players in biopharma manufacturing in the region.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
List of tables and figures and dummy in nature, final lists may vary in the final deliverable